Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Enanta Pharmaceuticals describes new MAP3K5 inhibitors

Nov. 21, 2019

Rat homologue of FX-201 decreases incidence and severity of osteoarthritis-related lesions

Nov. 21, 2019

Enanta Pharmaceuticals patents MAP3K5 inhibitors

Nov. 20, 2019

DWP-212525, a next-generation therapeutic for autoimmune diseases

Nov. 20, 2019

A placebo-controlled, first-in-human phase I study of the anti-ADAMTS-5 nanobody M-6495

Nov. 19, 2019

CJ-15314: a novel JAK1 inhibitor for the treatment of rheumatoid arthritis

Nov. 19, 2019

Results presented from proof-of-concept phase I study of cenerimod

Nov. 18, 2019

I-Mab obtains Chinese IND clearance for phase I trials of TJM-2 in rheumatoid arthritis

Nov. 15, 2019

New phase II trial evaluates KN-019 in rheumatoid arthritis

Nov. 14, 2019

KINE-101, a novel synthetic peptide for rheumatoid arthritis

Nov. 14, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...